Skip to content

King Pharmaceuticals KG Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Selective Insurance Group logo
Selective Insurance GroupSIGI
-$25.61M-59.5%
Universal Insurance Holdings logo
Universal Insurance HoldingsUVE
-$2.24M+1.5%
Silvercrest Asset Management Group logo
Silvercrest Asset Management GroupSAMG
-$33.19M-7.8%
Lazard logo
LazardLAZ
-$562.69M+3.1%

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-71.3%
Enterprise value$184.93M-52.3%
P/E1.2×
P/S1.6×-27.7×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's change in accrued liabilities?
King Pharmaceuticals (KG) reported change in accrued liabilities of $5.56M in Q1 2026.
How has King Pharmaceuticals's change in accrued liabilities changed year-over-year?
King Pharmaceuticals's change in accrued liabilities increased by 2369.0% year-over-year, from -$245K to $5.56M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.